Virtus ETF Advisers’s Vor Biopharma VOR Stock Holding History

Virtus ETF Advisers’s Portfolio VOR Stock Details VOR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-629	Closed	-$76K	–	477
2022 Q1	$76K	Sell	629 -37	-6%	-$6.3K	0.03%	344
2021 Q4	$155K	Buy	666 +189	+40%	+$54.5K	0.06%	339
2021 Q3	$149K	Sell	477 -24	-5%	-$7.13K	0.07%	345
2021 Q2	$187K	Buy	+501	New	+$247K	0.08%	378

Other funds holding VOR

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

5VM

5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return

LCM

Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SCM

Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return

Virtus ETF Advisers's VOR Position: Q2 2022 in Review

Virtus ETF Advisers sold out of Vor Biopharma (VOR) in Q2 2022, closing a stake of 629 shares — an estimated $76K sold.

Virtus ETF Advisers first reported a position in VOR in Q2 2021 and held it in 4 quarters. The position peaked at $187K in Q2 2021. 49 funds tracked by Wall St. Rank hold VOR as of Q2 2022.

Virtus ETF Advisers reported no remaining Vor Biopharma position as of Q2 2022 after selling out during the quarter.
Virtus ETF Advisers sold 629 Vor Biopharma shares in Q2 2022, an estimated $76K.
Virtus ETF Advisers first reported a position in Vor Biopharma in Q2 2021 and held it in 4 quarters.
Virtus ETF Advisers's Vor Biopharma position peaked at $187K in Q2 2021.
49 funds tracked by Wall St. Rank held Vor Biopharma as of Q2 2022.

Based on Virtus ETF Advisers's 13F filing for Q2 2022, filed 12 Aug 2022.